Over-expression of the HER 2 oncoprotein irrespective of hormone receptor status (HER2 HR+/−) is a well-known adverse prognostic factor associated with poor relapse free (RFS) and over all survival (OS) in breast cancer [9]. This evidence concerns the gene ERBB2 and breast carcinoma.